Content about VP regulatory affairs

September 8, 2011

Novo Nordisk has appointed a new VP regulatory affairs.

PRINCETON, N.J. — Novo Nordisk has appointed a new VP regulatory affairs.

Effective Sept. 12, Eddie Li will lead the drug maker's U.S. regulatory team and maintain relationships with individuals and agencies outside of Novo Nordisk that play a role in the Food and Drug Administration's review and approval process, the company said.

Li will report to Anne Philips, corporate VP clinical development, medical and regulatory affairs for North America.

February 1, 2011

As soon as members of Congress took their seats last month, the new Republican majority announced it would make good on its pledge to repeal the Patient Protection and Affordable Care Act. The effort largely is symbolic and unlikely to succeed, so at least one portion of the healthcare-reform law will likely remain in effect, namely the abbreviated approval pathway for follow-on biologics, also known as the Biologics Price Competition and Innovation Act.